⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4588115 | 0.80 | — | — | |
| SCHEMBL23999395 | 0.78 | — | — | |
| SCHEMBL12113242 | 0.78 | — | — | |
| SCHEMBL25111818 | 0.78 | — | — | |
| SCHEMBL19964144 | 0.75 | — | — | |
| SCHEMBL14941197 | 0.74 | DRD3 (0.38) | — | |
| SCHEMBL1944719 | 0.74 | EPHX2 (0.32) | — | |
| SCHEMBL28766847 | 0.72 | GLB1 (0.37) | — | |
| Hydrochloric Acid SCHEMBL28092151 | 0.72 | KMT2A (0.31) | — | |
| SCHEMBL29257701 | 0.72 | SMN1; SMN2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | claimed |
| CN-104105691-A | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC | 2014-10-15 | — | — | CN | claimed |
| EP-2776407-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2013070657-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2023142600-A1 | AMINO LIPID, PREPARATION METHOD THEREFOR, AND USE THEREOF | 深圳虹信生物科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| EP-4215188-A1 | AN AMINO LIPID, PREPARATION METHOD AND APPLICATION THEREOF | Shenzhen MagicRNA Biotechnology Co., Ltd. (CN) | 2023-07-26 | — | — | EP | disclosed |
| US-11033629-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200085961-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | CARA THERAPEUTICS, INC. | 2020-03-19 | — | — | US | disclosed |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | disclosed |
| CN-104105691-A | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC | 2014-10-15 | — | — | CN | disclosed |
| EP-2776407-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013070657-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-7524852-B2 | Bicyclic pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| WO-2008148074-A2 | INHIBITORS OF MTOR AND METHODS OF TREATMENT USING SAME | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2008-12-04 | — | — | WO | disclosed |
| CN-1232483-C | Method and apparatus for separating and purifying conjugated diene | NIPPON ZEON CO (JP) | 2005-12-21 | — | — | CN | disclosed |
| CN-1558885-A | Method and apparatus for separating and purifying conjugated diene | �ձ�������ʽ���� | 2004-12-29 | — | — | CN | disclosed |